Exosurf treatment following wood smoke inhalation.
Pulmonary surfactant deactivation is an important factor in the pathophysiology caused by wood smoke inhalation. Surfactant replacement is beneficial in treatment of surfactant-deficient neonates and possibly the adult respiratory distress syndrome (ARDS). In this study, the effect of exogenous Exosurf treatment for acute wood smoke injury was examined in four groups of rabbits. All groups were anaesthetized, placed on a ventilator, and surgically prepared for haemodynamic, peak airway pressure (P(aw)), and blood gas measurements. Rabbits were monitored for 2 h following smoke or sham smoke inhalation. At the conclusion of the experiment pulmonary oedema and surfactant function were measured. A Control group (n = 5) was followed without intervention. A Smoke group (n = 4) was ventilated with wood smoke for 3 min. A third group (Smoke+Exo, n = 4) was subjected to smoke followed by pulmonary instillation of Exosurf (5 ml/kg). Saline (5 ml/kg) was instilled into the lungs of the fourth group (n = 3) as a control for Exosurf instillation. Saline, Smoke and Smoke+Exo all significantly lowered PO2 and elevated P(aw) compared to baseline and the Control group. Exosurf treatment did not reduce the pulmonary oedema or restore surfactant function caused by smoke exposure. This study indicates that wood smoke inhalation acutely damages the lung and that administration of Exosurf by instillation is not an effective treatment.
Feldbaum
D M
DM
Department of Surgery, SUNY Health Science Center, Syracuse.
Wormuth
D
D
Nieman
G F
GF
Paskanik
M
M
Clark
W R
WR
Hakim
T S
TS
D000403:Airway Resistance; D000818:Animals; D002245:Carbon Dioxide / Q000097:blood; D004338:Drug Combinations; D015633:Extravascular Lung Water; D005233:Fatty Alcohols / Q000008:administration & dosage*; D007322:Instillation, Drug; D008168:Lung; D008170:Lung Compliance; D010100:Oxygen / Q000097:blood; D010767:Phosphorylcholine; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011654:Pulmonary Edema / Q000209:etiology / Q000473:pathology; D011663:Pulmonary Surfactants / Q000008:administration & dosage*; D011817:Rabbits; D015208:Smoke Inhalation Injury / Q000097:blood / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D013500:Surface Tension; D014934:Wood
D004338:Drug Combinations; D005233:Fatty Alcohols; D011663:Pulmonary Surfactants; D010767:Phosphorylcholine; D002245:Carbon Dioxide; D011092:Polyethylene Glycols; C047049:dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination; D010100:Oxygen